Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Melanoma 1Lymphoma, Mantle-Cell 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Trastuzumab 304Paclitaxel 257Cyclophosphamide 251Docetaxel 238Capecitabine 176Letrozole 163Carboplatin 163Fulvestrant 145Doxorubicin 145Bevacizumab 121Anastrozole 106Tamoxifen 102exemestane 94Vinorelbine 91Epirubicin 90pertuzumab 89Gemcitabine 84Lapatinib 80Albumin-Bound Paclitaxel 74Radiotherapy 71pembrolizumab 70palbociclib 64130-nm albumin-bound paclitaxel 58eribulin 56Cisplatin 55Everolimus 49pyrotinib 45Taxes 44Goserelin 43Neoadjuvant Therapy 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Breast Neoplasms × dinaciclib × Clear all
NCT00732810 2015-08-05

SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

Merck Sharp & Dohme LLC

Phase 2 Completed
97 enrolled
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡